沈琳 主任醫(yī)師、教授，北京學(xué)者

沈琳，主任醫(yī)師、教授、博士生導(dǎo)師。歷任北京大學(xué)腫瘤醫(yī)院副院長(zhǎng)、北京市腫瘤防治研究所副所長(zhǎng)?，F(xiàn)任消化腫瘤內(nèi)科主任、I期臨床試驗(yàn)病區(qū)主任，北京市政協(xié)委員。擔(dān)任中國(guó)抗癌協(xié)會(huì)腫瘤藥物臨床研究專業(yè)委員會(huì)首屆主任委員、中國(guó)抗癌協(xié)會(huì)腫瘤精準(zhǔn)治療專業(yè)委員會(huì)主任委員、中國(guó)臨床腫瘤學(xué)會(huì)臨床研究專家委員會(huì)主任委員、中國(guó)女醫(yī)師協(xié)會(huì)臨床腫瘤專業(yè)委員主任委員等多個(gè)重要學(xué)術(shù)職務(wù)。享受國(guó)務(wù)院政府特殊津貼，獲全國(guó)優(yōu)秀科技工作者、全國(guó)三八紅旗手榮譽(yù)稱號(hào)，入選北京學(xué)者、北京市突出貢獻(xiàn)專家。獲國(guó)家科技進(jìn)步二等獎(jiǎng)、教育部科技進(jìn)步一等獎(jiǎng)、中華醫(yī)學(xué)科技獎(jiǎng)一等獎(jiǎng)、中國(guó)抗癌協(xié)會(huì)科技獎(jiǎng)一等獎(jiǎng)、華夏醫(yī)學(xué)科技獎(jiǎng)一等獎(jiǎng)及二等獎(jiǎng)等多項(xiàng)獎(jiǎng)項(xiàng)。

主要研究方向：

沈琳教授長(zhǎng)期從事消化道腫瘤精準(zhǔn)治療，抗腫瘤新藥臨床與轉(zhuǎn)化研究。

主要研究成果包括：

帶領(lǐng)團(tuán)隊(duì)建立消化道腫瘤臨床與轉(zhuǎn)化研究體系，并入選2022年中國(guó)科協(xié)“科創(chuàng)中國(guó)”先導(dǎo)技術(shù)榜。牽頭眾多抗腫瘤新藥臨床研究，推動(dòng)抗腫瘤新藥獲批上市。以第一或責(zé)任作者在Nature, BMJ, Nature Medicine, JCO等權(quán)威期刊發(fā)表SCI論文近200篇，獲國(guó)家專利10項(xiàng)。撰寫40余部國(guó)際國(guó)內(nèi)胃腸道腫瘤診療規(guī)范。獲國(guó)家科技進(jìn)步二等獎(jiǎng)、教育部科技進(jìn)步一等獎(jiǎng)、中華醫(yī)學(xué)科技獎(jiǎng)一等獎(jiǎng)、中國(guó)抗癌協(xié)會(huì)科技獎(jiǎng)一等獎(jiǎng)、華夏醫(yī)學(xué)科技獎(jiǎng)一等獎(jiǎng)及二等獎(jiǎng)等多項(xiàng)獎(jiǎng)項(xiàng)。

承擔(dān)課題

國(guó)家重點(diǎn)研發(fā)計(jì)劃慢病專項(xiàng)首席科學(xué)家，承擔(dān)國(guó)家重點(diǎn)研發(fā)計(jì)劃、國(guó)家自然科學(xué)基金重大研究計(jì)劃、國(guó)家自然科學(xué)基金面上項(xiàng)目、國(guó)家自然科學(xué)基金面上項(xiàng)目、科技重大專項(xiàng)重大新藥創(chuàng)制項(xiàng)目、973計(jì)劃、863計(jì)劃、北京市自然科學(xué)基金重點(diǎn)項(xiàng)目、首都市民健康項(xiàng)目培育項(xiàng)目等多項(xiàng)課題，并取得較大成果。

發(fā)表的代表性論文(第一#或責(zé)任作者*)

1. Lu Z, Zou J, Li S, Topper M, Tao Y, Zhang H, Jiao X, Xie W, Kong X, Vaz M, Li H, Cai Y, Xia L, Huang P, Rodgers K, Lee B, Riemer J, Day C, Yen R, Cui Y, Wang Y, Wang Y, Zhang W, Easwaran H, Hulbert A, Kim K, Juergens R, Yang S, Battafarano R, Bush E, Broderick S, Cattaneo S, Brahmer J, Rudin C, Wrangle J, Mei Y, Kim Y J, Zhang B, Wang K, Forde P, Margolick J, Nelkin B, Zahnow C, Pardoll D, Housseau F, Baylin S, Shen L*, Brock M. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020;579(7798):284-290. IF：42.778

2. Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L*. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022 Apr 19;377:e068714. IF：105.7

3. Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L*. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Medicine. 2022 Jun;28(6):1189-1198. IF：82.9

4. Shen L#*, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol. 2022 Sep 10;40(26):3065-3076. IF：45.3

5. Lu Z, Fang Y, Liu C, Zhang X, Xin X, He Y, Cao Y, Jiao X, Sun T, Pang Y, Wang Y, Zhou J, Qi C, Gong J, Wang X, Li J, Tang L, Shen L*. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. 2021 Mar 1; 39(7):748-756. IF：44.544

6. Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L*, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-1092. IF：41.316

7. Zhao S, Lv C, Gong J, Wenfeng F, Hu X, Ba Y, Xiaoyuan C, Zhimin Y, Shen L*, Zhang L. Chinese Phase 1 Oncology trial Consortium. Challenges in anticancer drug R&D in China. Lancet Oncol. 2019 Feb;20(2):183-186. IF：35.386

8. Shen L#, Shan YS, Hu HM, Price T, Sirohi B, Yeh K, Yang Y, Sano T, Yang H, Zhang X, Park S, Fujii M, Kang Y, Chen L. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14(12):e535-e547. IF：25.117

9. Chen Y, Jia K, Sun Y, Zhang C, Li Y, Zhang L, Chen Z, Zhang J, Hu Y, Yuan J, Zhao X, Li Y, Gong J, Dong B, Zhang X, Li J, Shen L*. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nature Communications. (2022) 13:4851. IF：16.6

10. Zhang C, Chong X, Jiang F, Gao J, Chen Y, Jia K, Fan M, Liu X, An J, Li J, Zhang X, Shen L*. Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. Journal of Extracellular Vesicles. 2022 Apr;11(4):e12209. IF：25.841